Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | CASP7 | P55210 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.39 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25322168 | 1.00 | CASP3 (0.43) | CASP3CASP7FFAR1ALDH1A1GAA | |
| SCHEMBL27031270 | 0.92 | ALDH1A1 (0.44) | CASP3CASP7FFAR1ALDH1A1CYP2D6 | |
| SCHEMBL9068328 | 0.89 | ALDH1A1 (0.46) | CASP3CASP7ALDH1A1GAAPOLB | |
| SCHEMBL2302585 | 0.87 | FFAR1 (0.45) | CASP3CASP7FFAR1ALDH1A1GAA | |
| SCHEMBL3129424 | 0.87 | FFAR1 (0.45) | CASP3CASP7FFAR1ALDH1A1GAA | |
| SCHEMBL3616703 | 0.87 | FFAR1 (0.45) | CASP3CASP7FFAR1ALDH1A1GAA | |
| SCHEMBL16538611 | 0.86 | GPR119 (0.45) | CASP3CASP7LMNA | |
| SCHEMBL16538625 | 0.86 | GPR119 (0.45) | CASP3CASP7LMNA | |
| SCHEMBL5133068 | 0.83 | ALDH1A1 (0.46) | FFAR1ALDH1A1CYP2D6FKBP1APOLB | |
| SCHEMBL2678802 | 0.83 | ALDH1A1 (0.46) | FFAR1ALDH1A1CYP2D6FKBP1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | CASP3 583/4885CASP7 18/4885FFAR1 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.